^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MNPR 101
i
Other names: MNPR 101, ATN-658, huATN-658, Humanised ATN-658, MNPR-101, MNPR101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Monopar Therapeutics, Xoma
Drug class:
uPAR inhibitor
Related drugs:
7ms
MNPR101-Lu-1-01: Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors (clinicaltrials.gov)
P1, N=12, Recruiting, Monopar Therapeutics | Trial completion date: Jun 2025 --> Jan 2027 | Trial primary completion date: Jun 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
MNPR 101
7ms
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer (clinicaltrials.gov)
P=N/A, N=0, Available, Monopar Therapeutics
New trial
|
MNPR 101
7ms
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer (clinicaltrials.gov)
P=N/A, N=0, Available, Monopar Therapeutics
New trial
|
MNPR 101
1year
MNPR101-Lu-1-01: Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors (clinicaltrials.gov)
P1, N=12, Recruiting, Monopar Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
MNPR 101
1year
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Monopar Therapeutics
New P1 trial
|
MNPR 101
almost5years
A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma. (PubMed, Eur J Cancer)
MNPR-101-IRDye800CW is suitable for multimodal imaging of UCC, awaiting clinical translation.
Journal
|
EPCAM (Epithelial cell adhesion molecule)
|
EPCAM expression
|
Rituxan (rituximab) • MNPR 101
Share via
